PLUR
Pluri Inc.
NASDAQ · Healthcare · Biotechnology · IL
$1.43
+4.06%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
Market Cap
$17.09M
MomentumView details →
1D Return
+4.06%
YTD Return
−52.51%
RSI (14)
38.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
Market Cap
$17.09M
RSI (14)
38.2
MomentumView details →
1D Return
+4.06%
YTD Return
−52.51%
SummaryUpdated Mar 1, 2026
Pluri Inc. (NASDAQ:PLUR) is an Israeli biotechnology company founded in 2001 and headquartered in Haifa, Israel. Originally incorporated as Pluristem Therapeutics Inc., the company rebranded to Pluri Inc. in July 2022. The company went public in 2003 and has been developing innovative cell therapy treatments for over two decades. Pluri specializes in creating therapeutic products derived from placental cells, focusing on treating inflammatory conditions, muscle injuries, and blood-related disorders through its proprietary placental expanded (PLX) cell therapy platform.
Similar companies
Latest newsMore news →
Pluri Inc. priced a registered direct offering and concurrent private placement of 2,228,940 common shares at $1.50 per share to a single healthcare-focused institutional investor, expecting gross proceeds of approximately $3.3 million.8d agoPluri Inc.'s subsidiary Cellav completed cosmetic regulatory registration in the UK for its regenerative aesthetics product Regenativo+.38d ago